Roche today announced data from its "Addressing the Need for Advanced HPV Diagnostics," or ATHENA, trial in the US to test the ability of its PCR-based genotyping test to identify women with cervical pre-cancer missed by cytological examination with a Pap test.

The trial, which examined more than 47,000 women, demonstrated that one in 10 women age 30 years and older who had a normal Pap test but who tested positive for HPV genotypes 16 and/or 18 with Roche's Cobas 4800 HPV test, had cervical precancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.